NASDAQ:ARDS - Aridis Pharmaceuticals Stock Price, Forecast & News

Aridis Pharmaceuticals trades on the NASDAQ under the ticker symbol "ARDS."

Aridis Pharmaceuticals Inc (NASDAQ:ARDS) posted its quarterly earnings results on Wednesday, November, 13th. The company reported ($0.87) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.33) by $0.54. View Aridis Pharmaceuticals' Earnings History.

Aridis Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, March 26th 2020. View Earnings Estimates for Aridis Pharmaceuticals.

4 brokerages have issued 12-month price targets for Aridis Pharmaceuticals' stock. Their forecasts range from $7.00 to $25.00. On average, they expect Aridis Pharmaceuticals' share price to reach $17.25 in the next year. This suggests a possible upside of 141.0% from the stock's current price. View Analyst Price Targets for Aridis Pharmaceuticals.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aridis Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Aridis Pharmaceuticals.

Press coverage about ARDS stock has been trending very negative recently, InfoTrie reports. InfoTrie identifies positive and negative media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Aridis Pharmaceuticals earned a daily sentiment score of -3.3 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 2.0 out of 10, indicating that recent media coverage is very unlikely to have an impact on the company's share price in the next several days. View News Stories for Aridis Pharmaceuticals.

Some companies that are related to Aridis Pharmaceuticals include Hookipa Pharma (HOOK), Wave Life Sciences (WVE), Neptune Wellness Solutions (NEPT), Concert Pharmaceuticals (CNCE), Sol Gel Technologies (SLGL), BIOFRONTERA AG/ADR (BFRA), Kala Pharmaceuticals (KALA), Avadel Pharmaceuticals (AVDL), Evofem Biosciences (EVFM), MEI Pharma (MEIP), VBI Vaccines (VBIV), Seres Therapeutics (MCRB), Evelo Biosciences (EVLO), LifeVantage (LFVN) and Athersys (ATHX).

Based on aggregate information from My MarketBeat watchlists, some companies that other Aridis Pharmaceuticals investors own include Juno Therapeutics (JUNO), Anavex Life Sciences (AVXL), Nektar Therapeutics (NKTR), Progenics Pharmaceuticals (PGNX), Tandem Diabetes Care (TNDM), Abeona Therapeutics (ABEO), Aclaris Therapeutics (ACRS), Applied Genetic Technologies (AGTC), Fate Therapeutics (FATE) and Genocea Biosciences (GNCA).

(ARDS) raised $28 million in an IPO on Tuesday, August 14th 2018. The company issued 2,000,000 shares at $13.00-$15.00 per share. Cantor acted as the underwriter for the IPO and Maxim Group and Northland Capital Markets were co-managers.

Shares of ARDS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ARDS stock can currently be purchased for approximately $7.16.

Aridis Pharmaceuticals has a market capitalization of $63.77 million and generates $2.76 million in revenue each year. The company earns $-22,100,000.00 in net income (profit) each year or ($7.01) on an earnings per share basis. Aridis Pharmaceuticals employs 23 workers across the globe.View Additional Information About Aridis Pharmaceuticals.

The official website for Aridis Pharmaceuticals is http://www.aridispharma.com/.

Aridis Pharmaceuticals' mailing address is 5941 Optical Ct., San Jose CA, 95138. The company can be reached via phone at 408-385-1742 or via email at [email protected]